Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A versus placebo and vedolizumab in moderate to severe ulcerative colitis
2017-002350-36Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efmarodocokin alfa in autoimmune colitis (3 arms), sponsored by Genentech. Primary endpoint: Clinical remission. Started Apr 2018; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-002350-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002350-36.